With recent technological advances, the contribution that imaging makes to the care of cancer patients goes well beyond tumor morphology. Advanced MRI sequences and sophisticated image analysis software have enabled the detection of specific biological processes, which reflect cancer behavior, including tumor aggressiveness and response to treatment. In breast imaging, dynamic contrast enhanced (DCE) sequences play key roles in cancer detection and characterization (
1). Thus, advanced DCE sequences have the potential to revolutionize breast cancer imaging. Indeed, such MRI sequences are characterized by high temporal resolution, enabling the acquisition of multiple repeated images in a short time interval and, through the application of a pharmacokinetic model, to analyze the transfer of contrast agent through the capillary vessel wall, a process strongly related to tissue permeability and neoangiogenesis. Such biological phenomena are described by quantitative values, such as the contrast transfer from the vessel to the extravascular extracellular space (Ktrans) and vice-versa (Kep), the amount of contrast agent within the vessel (plasma volume) and in the EES (Ve) (
- Pinker K
- Helbich TH
- Morris EA.
The potential of multiparametric MRI of the breast.
Br J Radiol. 2017; https://doi.org/10.1259/bjr.20160715
2). Several studies explored the role of such parameters in different imaging tasks, including differentiating benign from malignant breast lesions, characterizing breast cancer aggressiveness, predicting patients’ prognosis and the early assessment of the response to neoadjuvant chemotherapy (
- Bernstein JM
- Kershaw LE
- Withey SB
- et al.
Tumor plasma flow determined by dynamic contrast-enhanced MRI predicts response to induction chemotherapy in head and neck cancer.
Oral Oncol. 2015; https://doi.org/10.1016/j.oraloncology.2015.01.013
- Kim Y
- Kim SH
- Song BJ
- et al.
Early prediction of response to neoadjuvant chemotherapy using dynamic contrast-enhanced MRI and ultrasound in breast cancer.
Korean J Radiol. 2018; https://doi.org/10.3348/kjr.2018.19.4.682
- Margolis NE
- Moy L
- Sigmund EE
- et al.
Assessment of aggressiveness of breast cancer using simultaneous 18F-FDG-PET and DCE-MRI.
Clin Nucl Med. 2016; https://doi.org/10.1097/RLU.0000000000001254
- Liu F
- Wang M
- Li H.
Role of perfusion parameters on DCE-MRI and ADC values on DWMRI for invasive ductal carcinoma at 3.0 Tesla.
World J Surg Oncol. 2018; https://doi.org/10.1186/s12957-018-1538-8
6). This last possible application represents one of the most fascinating uses of quantitative DCE-MRI parameters, if we consider that changes in tumor biology are supposed to occur earlier than the morphologic ones (
- Lee J
- Kim SH
- Kang BJ.
Pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: perfusion metrics of dynamic contrast enhanced MRI.
Sci Rep. 2018; https://doi.org/10.1038/s41598-018-27764-9
7). Thus, changes of perfusion parameters after the first chemotherapy cycles may early reflect tumor response or resistance. Moreover, pre-treatment values might reflect the tumor vascular asset, providing important information related to drug delivery and, therefore, treatment response.
- Romeo V
- Accardo G
- Perillo T
- et al.
Assessment and prediction of response to neoadjuvant chemotherapy in breast cancer: A comparison of imaging modalities and future perspectives.
Cancers (Basel). 2021; https://doi.org/10.3390/cancers13143521
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Academic Radiology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- The potential of multiparametric MRI of the breast.Br J Radiol. 2017; https://doi.org/10.1259/bjr.20160715
- Tumor plasma flow determined by dynamic contrast-enhanced MRI predicts response to induction chemotherapy in head and neck cancer.Oral Oncol. 2015; https://doi.org/10.1016/j.oraloncology.2015.01.013
- Early prediction of response to neoadjuvant chemotherapy using dynamic contrast-enhanced MRI and ultrasound in breast cancer.Korean J Radiol. 2018; https://doi.org/10.3348/kjr.2018.19.4.682
- Assessment of aggressiveness of breast cancer using simultaneous 18F-FDG-PET and DCE-MRI.Clin Nucl Med. 2016; https://doi.org/10.1097/RLU.0000000000001254
- Role of perfusion parameters on DCE-MRI and ADC values on DWMRI for invasive ductal carcinoma at 3.0 Tesla.World J Surg Oncol. 2018; https://doi.org/10.1186/s12957-018-1538-8
- Pretreatment prediction of pathologic complete response to neoadjuvant chemotherapy in breast cancer: perfusion metrics of dynamic contrast enhanced MRI.Sci Rep. 2018; https://doi.org/10.1038/s41598-018-27764-9
- Assessment and prediction of response to neoadjuvant chemotherapy in breast cancer: A comparison of imaging modalities and future perspectives.Cancers (Basel). 2021; https://doi.org/10.3390/cancers13143521
- Tumor segmentation analysis at different post-contrast time points: a possible source of variability of quantitative DCE-MRI parameters in locally advanced breast cancer.Eur J Radiol. 2020; https://doi.org/10.1016/j.ejrad.2020.108907
- Difference of DCE-MRI parameters at different time points and their predictive value for axillary lymph node metastasis of breast cancer.Acad Radiol. 2021; https://doi.org/10.1016/j.acra.2021.01.013
- Simultaneous PET/MRI assessment of response to cytotoxic and hormone neo-adjuvant chemotherapy in breast cancer: a preliminary report.Med Oncol. 2017; 34https://doi.org/10.1007/s12032-016-0876-z
- Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging.Radiology. 2014; https://doi.org/10.1148/radiol.14131332
- Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI.Breast. 2012; https://doi.org/10.1016/j.breast.2012.07.006
- Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results.Radiology. 2006; https://doi.org/10.1148/radiol.2392021099
- Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.Clin Cancer Res. 2008; https://doi.org/10.1158/1078-0432.CCR-07-4310
Published online: January 03, 2022
Accepted: December 5, 2021
Received: December 5, 2021
© 2021 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.